Drug intelligence / Profile preview

LY3938577

Development stage: Phase 2
Lead developer: Eli Lilly
Modality: Small Molecules
Administration: Subcutaneous, Intravenous

Overview

LY3938577 is an investigational antihyperglycemic drug under development by Eli Lilly and Company for the treatment of type 2 diabetes mellitus and type 1 diabetes. It is a new molecular entity currently in Phase I clinical trials. The drug is administered via subcutaneous or intravenous routes. While its precise mechanism of action has not been fully defined, it is reported to act by targeting the glucose sensing insulin receptor, aiming to improve glycemic control in diabetic patients[1][3]. Clinical studies are ongoing to evaluate its safety, tolerability, pharmacokinetics, and blood sugar-lowering effects compared to standard therapies such as Insulin Degludec[8].

Other names: Glucose-sensing insulinGSI

Targets

INSR (Insulin receptor)

Beyond the preview

Go deeper on LY3938577.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LY3938577.

Explore the full profile